Florida Judge Dismisses Rival Patent Suit Alleging Trulieve Infringed THC-Related Patents

# What happened On Sept. 28, 2026, a Florida federal judge granted cannabis company Trulieve Inc.'s motion to dismiss a complaint filed by a rival patent-holding company. The complaint alleged that Trulieve infringed several patents related to cannabinoid chemistry and processing.

# Case context and parties

# Patents at issue The complaint challenged multiple patents focused on methods for modifying and decarboxylating cannabinoids. Law360's article lists these patents and their general subject matter:

• U.S. Patent No. 10,669,248 — Methods to chemically modify cannabinoids
• U.S. Patent No. 11,643,402 — Gas phase methods to decarboxylate cannabinoids
• U.S. Patent No. 12,297,181 — Methods to chemically modify cannabinoids
• U.S. Patent No. 12,420,214 — Methods to produce products comprising cannabinoids

These patent numbers and short descriptions were reported in the article's case information.

# Ruling and immediate effect The judge granted Trulieve's request to toss the complaint. The article does not provide the court's detailed reasoning, specific legal grounds for dismissal, or whether the dismissal was with or without prejudice. No further case-management steps, appeals, or replacement pleadings are described in the published summary.

# Court and personnel

# Why this matters to stakeholders For Trulieve, the dismissal removes a currently pending federal allegation of patent infringement tied to cannabinoid processing methods. For patent holders and cannabis industry participants, the dispute illustrates ongoing litigation activity around chemical-processing and formulation patents in the cannabis space. Law firms listed on the case suggest experienced IP and litigation counsel are handling the matter.

# What the article does not provide here The published summary does not include: the plaintiff's name, the complaint's allegations in detail, the judge's written opinion or the legal basis for dismissal, whether leave to amend was allowed, or whether either side plans to appeal or refile. The summary also does not report on any parallel proceedings before the Patent Trial and Appeal Board or the International Trade Commission.

# Practical takeaway The federal court dismissal reduces immediate litigation risk for Trulieve on the specific claims reported. Companies working with cannabinoid-processing methods should track follow-up filings and any written opinion for precedent or guidance on how courts are treating claims that target chemical modification and decarboxylation techniques.